Beam Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 6, 2025

BEAM$27.02+2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	March 31,2025	December 31,2024
Assets
Current assets:
Cash and cash equivalents	$527,907	$281,967
Marketable securities	692,045	568,773
Prepaid expenses and other current assets	27,662	27,409
Total current assets	1,247,614	878,149
Property and equipment, net	109,569	111,412
Restricted cash	6,610	8,144
Operating lease right-of-use assets	102,216	104,865
Other assets	911	1,254
Total assets	$1,466,920	$1,103,824
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$7,699	$3,871
Accrued expenses and other current liabilities	30,233	47,468
Current portion of derivative liabilities	5,200	8,400
Current portion of deferred revenue	85,204	108,858
Current portion of lease liability	13,210	13,469
Total current liabilities	141,546	182,066
Long-term lease liability	144,919	147,956
Contingent consideration liabilities	1,158	1,131
Long-term portion of deferred revenue	49,403	33,218
Long-term portion of derivative liabilities	6,344	5,404
Other liabilities	414	504
Total liabilities	343,784	370,279
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2025 and December 31, 2024, respectively	—	—
Common stock, $0.01 par value; 250,000,000 shares authorized, 100,557,094 and 83,633,069 issued and outstanding at March 31, 2025 and December 31, 2024, respectively	1,006	836
Additional paid-in capital	2,797,871	2,298,661
Accumulated other comprehensive (loss) income	160	679
Accumulated deficit	(1,675,901)	(1,566,631)
Total stockholders’ equity	1,123,136	733,545
Total liabilities and stockholders’ equity	$1,466,920	$1,103,824

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.